Udo Eichenlaub

4.8k total citations · 5 hit papers
32 papers, 2.8k citations indexed

About

Udo Eichenlaub is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Udo Eichenlaub has authored 32 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Physiology, 18 papers in Psychiatry and Mental health and 9 papers in Molecular Biology. Recurrent topics in Udo Eichenlaub's work include Alzheimer's disease research and treatments (19 papers), Dementia and Cognitive Impairment Research (17 papers) and Functional Brain Connectivity Studies (7 papers). Udo Eichenlaub is often cited by papers focused on Alzheimer's disease research and treatments (19 papers), Dementia and Cognitive Impairment Research (17 papers) and Functional Brain Connectivity Studies (7 papers). Udo Eichenlaub collaborates with scholars based in Germany, United States and Sweden. Udo Eichenlaub's co-authors include Kaj Blennow, Henrik Zetterberg, Oskar Hansson, Erik Stomrud, Niklas Mattsson, Sebastian Palmqvist, Tobias Bittner, Jeffrey L. Dage, Xiyun Chai and Shorena Janelidze and has published in prestigious journals such as Nature Medicine, Neurology and Scientific Reports.

In The Last Decade

Udo Eichenlaub

31 papers receiving 2.8k citations

Hit Papers

Plasma P-tau181 in Alzheimer’s disease: relationship to o... 2018 2026 2020 2023 2020 2018 2019 2021 2019 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
    2020 765 citations Shorena Janelidze, Niklas Mattsson et al. Nature Medicine profile →
  2. CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
    2018 485 citations Oskar Hansson, John Seibyl et al. Alzheimer s & Dementia profile →
  3. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
    2019 299 citations Sebastian Palmqvist, Shorena Janelidze et al. JAMA Neurology profile →
  4. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
    2021 267 citations Shorena Janelidze, Charlotte E. Teunissen et al. JAMA Neurology profile →
  5. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
    2019 230 citations Sebastian Palmqvist, Erik Stomrud et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Udo Eichenlaub Germany 14 2.0k 1.8k 588 517 366 32 2.8k
Suzanne E. Schindler United States 28 1.7k 0.9× 1.7k 0.9× 435 0.7× 641 1.2× 390 1.1× 120 3.2k
Andréa Lessa Benedet Canada 30 1.8k 0.9× 1.4k 0.8× 519 0.9× 497 1.0× 449 1.2× 101 2.7k
Juan Lantero‐Rodriguez Sweden 26 1.8k 0.9× 1.4k 0.8× 424 0.7× 733 1.4× 239 0.7× 54 2.8k
Sarah E. Monsell United States 25 1.7k 0.9× 1.7k 1.0× 684 1.2× 396 0.8× 373 1.0× 59 3.3k
Małgorzata Knapik-Czajka Poland 9 1.4k 0.7× 1.3k 0.7× 374 0.6× 404 0.8× 394 1.1× 22 2.1k
Peder Buchhave Sweden 12 2.1k 1.1× 1.5k 0.9× 726 1.2× 639 1.2× 302 0.8× 13 2.8k
Xiyun Chai United States 8 1.9k 0.9× 1.2k 0.7× 611 1.0× 563 1.1× 218 0.6× 12 2.4k
Giovanni B. Frisoni Switzerland 22 1.1k 0.5× 1.0k 0.6× 369 0.6× 406 0.8× 407 1.1× 129 2.3k
S. Lance Macaulay Australia 23 2.0k 1.0× 1.6k 0.9× 548 0.9× 749 1.4× 628 1.7× 40 3.8k
Inge M.W. Verberk Netherlands 22 1.4k 0.7× 1.2k 0.7× 486 0.8× 473 0.9× 188 0.5× 74 2.2k

Countries citing papers authored by Udo Eichenlaub

Since Specialization
Citations

This map shows the geographic impact of Udo Eichenlaub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Udo Eichenlaub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Udo Eichenlaub more than expected).

Fields of papers citing papers by Udo Eichenlaub

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Udo Eichenlaub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Udo Eichenlaub. The network helps show where Udo Eichenlaub may publish in the future.

Co-authorship network of co-authors of Udo Eichenlaub

This figure shows the co-authorship network connecting the top 25 collaborators of Udo Eichenlaub. A scholar is included among the top collaborators of Udo Eichenlaub based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Udo Eichenlaub. Udo Eichenlaub is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jochum, Simon, et al.. (2022). Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial. Frontiers in Immunology. 12. 798117–798117. 39 indexed citations
2.
Ortner, Marion, Udo Eichenlaub, Oliver Goldhardt, et al.. (2022). The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. Alzheimer s Research & Therapy. 14(1). 36 indexed citations
3.
Grunert, Veit Peter, Holly Legault, Maha Maglinao, et al.. (2022). Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19. Infectious Diseases and Therapy. 12(1). 177–191. 5 indexed citations
4.
Palmqvist, Sebastian, Erik Stomrud, Nicholas Cullen, et al.. (2022). An accurate fully automated panel of plasma biomarkers for Alzheimer's disease. Alzheimer s & Dementia. 19(4). 1204–1215. 96 indexed citations
5.
Provost, Karine, Leonardo Iaccarino, David N. Soleimani‐Meigooni, et al.. (2021). Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging. 48(7). 2259–2271. 17 indexed citations
6.
Janelidze, Shorena, Charlotte E. Teunissen, Henrik Zetterberg, et al.. (2021). Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. JAMA Neurology. 78(11). 1375–1375. 267 indexed citations breakdown →
7.
Bittner, T., Thomas Duning, Christina Rabe, et al.. (2020). P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results. Clinical Neurophysiology. 131(4). e194–e195. 4 indexed citations
8.
Janelidze, Shorena, Niklas Mattsson, Sebastian Palmqvist, et al.. (2020). Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nature Medicine. 26(3). 379–386. 765 indexed citations breakdown →
9.
Vilor‐Tejedor, Natàlia, Marta Milà‐Alomà, Eider M. Arenaza‐Urquijo, et al.. (2020). Genetically predicted telomere length and Alzheimer’s disease endophenotypes: A Mendelian randomization study. Alzheimer s & Dementia. 16(S10). 1 indexed citations
10.
Cacciaglia, Raffaele, José Luís Molinuevo, Gemma Salvadó, et al.. (2020). Impact of APOE‐ε4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. Alzheimer s & Dementia. 16(S1). 1 indexed citations
11.
Blennow, Kaj, Leslie M. Shaw, Erik Stomrud, et al.. (2019). Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays. Scientific Reports. 9(1). 19024–19024. 127 indexed citations
12.
Blennow, Kaj, Jeffrey L. Dage, Sterling C. Johnson, et al.. (2019). P2‐231: EXPLORING THE NEED FOR ROBUST BIOMARKER ASSAYS IN ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES. Alzheimer s & Dementia. 15(7S_Part_13).
13.
Palmqvist, Sebastian, Shorena Janelidze, Erik Stomrud, et al.. (2019). Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status. JAMA Neurology. 76(9). 1060–1060. 299 indexed citations breakdown →
14.
Shaw, Leslie M., Teresa Waligórska, Leona Fields, et al.. (2018). Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 10(1). 698–705. 54 indexed citations
15.
Palmqvist, Sebastian, Shorena Janelidze, Erik Stomrud, et al.. (2018). DT‐02‐04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA Aβ BIOMARKER ASSAYS. Alzheimer s & Dementia. 14(7S_Part_31). 1 indexed citations
16.
Seibyl, John, Kaj Blennow, Veronika Corradini, et al.. (2017). [O1–05–05]: AMYLOID‐PET CONCORDANCE OF ELECSYS® CSF BIOMARKER IMMUNOASSAYS FOR ALZHEIMER's DISEASE. Alzheimer s & Dementia. 13(7S_Part_4). 9 indexed citations
17.
18.
Nikolcheva, Tania, Robert Lasser, Susanne Ostrowitzki, et al.. (2016). CSF and amyloid pet biomarker data from scarlet road - a global Phase 3 study of gantenerumab in patients with prodromal AD. Neurobiology of Aging. 39. S28–S29. 3 indexed citations
19.
Bittner, Tobias, Henrik Zetterberg, Charlotte E. Teunissen, et al.. (2015). Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid. Alzheimer s & Dementia. 12(5). 517–526. 241 indexed citations
20.
Scheltens, Philip, Tania Nikolcheva, Robert Lasser, et al.. (2015). DT‐01‐02: Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease. Alzheimer s & Dementia. 11(7S_Part_7). 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suzanne E. Schindler Breakdown of academic impact, for papers by Andréa Lessa Benedet Breakdown of academic impact, for papers by Juan Lantero‐Rodriguez Breakdown of academic impact, for papers by Sarah E. Monsell Breakdown of academic impact, for papers by Małgorzata Knapik-Czajka Breakdown of academic impact, for papers by Peder Buchhave Breakdown of academic impact, for papers by Xiyun Chai Breakdown of academic impact, for papers by Giovanni B. Frisoni Breakdown of academic impact, for papers by S. Lance Macaulay Breakdown of academic impact, for papers by Inge M.W. Verberk
Rankless by CCL
2026